Correction of hypovitaminosis D improved global longitudinal strain earlier than left ventricular ejection fraction in cardiovascular older adults after orthopaedic surgery by M. Briguglio et al.
 Journal of Geriatric Cardiology (2018) 15: 519522 
 ©2018 JGC All rights reserved; www.jgc301.com 
  
http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology 
Research Article     Open Access  
 
Correction of hypovitaminosis D improved global longitudinal strain earlier 
than left ventricular ejection fraction in cardiovascular older adults after  
orthopaedic surgery 
 
Matteo Briguglio1, Luigi Gianturco1, Daniele Stella1, Chiara Colombo1, Marika Bonadies1, Oscar Sala1,  
Mauro Anselmi1, Giuseppe Banfi2,3, Maurizio Turiel1 
1IRCCS Orthopedic Institute Galeazzi, Cardiology Unit, Milan, Italy 
2IRCCS Orthopedic Institute Galeazzi, Scientific Direction, Milan, Italy 
3University Vita e Salute San Raffaele, Milan, Italy  
 
Abstract 
Background  Cardiovascular diseases and insufficient levels of vitamin D are risk factors for adverse surgical outcomes, and they are 
both commonly present among older adults undergoing orthopaedic surgery. Giving the cardiovascular effects of vitamin D, pre-operative 
diagnosis of hypovitaminosis D would be a valuable step for the implementation of supplementation protocols. We investigated if the nor-
malization of serum 25 [OH] D could ameliorate cardiac performance of older adults suffering from cardiovascular diseases. Methods  We 
enrolled 47 older adults scheduled for major orthopaedic surgery and suffering from hypovitaminosis D. Patients underwent 6-months cal-
cifediol supplementation with a starting dose at first post-operative day of 50 μg/die in liquid preparation. Down-titration to 20 μg/die at 
3-months assessment was planned. Cardiac performance was evaluated by measuring left ventricular ejection fraction (LVEF) and global 
longitudinal strain (GLS) during pre-operative assessments and at 1-month, 3-months, 6-months follow-ups. Results  Six months of cal-
cifediol supplementation were associated with a significant improvement of both LVEF (+ 3.94%; 95% CI: −4.0789 to −0.8232; P < 0.01) 
and GLS (+ 18.56%; Z = −5.895; P < 0.0001). Conclusions  Calcifediol supplementation normalized serum 25 [OH] D concentration after 
1-month treatment. GLS offered better insights into myocardial contractile amelioration than LVEF, thus being useful for detecting earlier 
subclinical changes that may anticipate hemodynamic modifications. 
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1  Introduction 
In orthopedic setting, surgeons consider pre-operative 
low serum level of 25 [OH] D a risk for adverse outcomes,[1] 
and supplementation protocols were implemented since 
years.[2] Likewise, cardiologists consider the presence of 
cardiovascular diseases, such as arrhythmia, heart failure, 
and acute myocardial infarction, a risk factor for post-op-
erative complications.[3,4] Recently, vitamin D supplementa-
tion received attention from cardiologists for its efficacy in 
improving previously compromised ventricular output.[5] 
With the highest prevalence of hypovitaminosis D found in  
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older adults undergoing orthopedic surgery[6] and its corre-
lation with co-morbid cardiovascular diseases,[7] pre-opera-
tive diagnosis of hypovitaminosis D would be a step of 
convergent interests between cardiologists and orthopedics, 
thus giving vitamin D supplementation a common role. 
Therefore, we investigated if the correction of hypovitami-
nosis D could ameliorate post-surgical cardiac performance 
of older adults in our orthopedic setting. 
2  Methods 
2.1  Study participants and evaluations 
Screening and recruitment were conducted among con-
secutive older adults referring to inpatient Cardiology Unit 
prior major orthopedic surgery at IRCCS Orthopaedic 
Galeazzi in Milan. Inclusion criteria were Caucasian race, 
age between 50–90 years old, presence of cardiovascular 
disease, and hypovitaminosis D. Exclusion criteria were 
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chronic kidney disease with glomerular filtration rate < 35 
mL/min, tumours in the last five years, and endocrine dis-
eases with the exception of obesity, diabetes mellitus type 1 
or 2, or dyslipidaemia. The chemiluminescent immunoassay 
ARCHITECT 25-OH Vitamin D (Abbott Diagnostics, USA) 
was used to determine calcifediol plasma concentrations: 
values < 32 ng/mL were considered indicative of low lev-
els.[8] All patients underwent transthoracic echocardiogra-
phy (TTE), which provided pre-operative left ventricular 
ejection fraction (LVEF) and global longitudinal strain 
(GLS) by using EPIC 7 ultrasound system (Philips, USA). 
The X5–1 transducer was used at a frequency of 5–1 MHz, 
in tandem with electrocardiography monitoring. Images 
were elaborated through Q-lab 10.5 software. After surgery, 
blood tests and TTE were performed at 1-month, 3-months, 
and 6-months follow-ups. 
2.2  Intervention and analysis 
A liquid preparation of calcifediol (i.e., oil-in-water 
emulsion with propylene glycol) to be administered by oral 
drops was used, instead of the more commonly used tablets, 
capsules, or powders. The dose was set at 50 μg/die, which 
was lower than the one used in other studies because of the 
absence of the first-pass effect,[9] and the higher matrix 
bioavailability and bioaccessibility ensured by the liquid 
preparation compared to solid dosages.[5] Therefore, the 
starting dose at first post-operative day was set to 10 drops 
(i.e., one drop = 5 μg calcifediol). At 1-month supplementa-
tion, dose was planned to be reduced to four drops in order 
to keep range between 32–60 ng/mL over remaining trial 
extent. The intention-to-treat analysis compared LVEF and 
GLS between baseline and follow-ups by using paired sam-
ples t-test for normally distributed values or Wilcoxon 
signed-rank test for skewed values. All tests were performed 
by using SPSS 22 and 2-tailed tests. Intra- and inter-obser-
ver variability was calculated using Bland-Altmann meth-
ods.[10] 
3  Results 
A total of 47 subjects completed the study, and baseline 
demographic and clinical data were expressed in Table 1. At 
1-month assessment, blood withdrawals for 25 [OH] D 
measured 60.95 ± 28.40 ng/mL (7.20; 117.70) and, accord-
ing to the protocol, drops were reduced to four per day. At 
3-months assessment, serum 25 [OH] D concentrations 
showed a mean of 58.20 ± 20.72 ng/mL (19.00; 145.70) and, 
not according to the protocol, drops were reduced to two per 
day. After six months, measured values of serum 25[OH]D 
were 43.06 ± 16.46 ng/mL (8.30; 82.00) and statistical  
Table 1.  Baseline demographic and clinical data of cardio-
vascular older adults undergoing 6-months supplementation of 
calcifediol in daily drops. 
 (n = 47) 
Age, yrs 70.23 ± 8.41 (53.00; 90.00)
Gender (male/female) 20 (43%) / 27 (57%) 
Body mass index, kg/m2 30.25 ± 5.13 (20.54; 42.06)
Number of cardiovascular diseases 2.00 (1.00/2.00) 
High blood pressure 37 (79%) 
Ischaemic heart disease 4 (8%) 
Arrhythmia 5 (11%) 
Heart valve problem 1 (2%) 
Vascular disease 6 (13%) 
Number of comorbidities 1.00 (0.00/2.00) 
Obesity 21 (45%) 
Dyslipidaemia 15 (32%) 
Diabetes mellitus type 2 8 (17%) 
Number of medications 3.00 (2.00/5.00) 
Beta-blockers 18 (38%) 
Ca blockers 12 (26%) 
ACEi/ARB/DRI 32 (68%) 
Diuretics 22 (47%) 
Anti-platelet, anti-integrin, anti-thrombotic 12 (26%) 
Anti-arrhythmics 5 (11%) 
25 [OH] D, ng/mL 16.33 ± 7.26 (4.90; 30.10) 
Left ventricular ejection fraction, % 62.26 ± 4.29 (52.00; 70.00)
Global longitudinal strain, % −18.17 ± 1.75 (−11.90; −22.80)
Continuous variables were reported as mean ± SD (min; max) or as median 
(Q1/Q3). Categorical variables were reported as frequencies and percent-
ages. ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin 
receptor blockers; DRI: direct renin inhibitor. 
 
analyses revealed a significant difference for plasma vita-
min D (P < 0.001; 95% CI: −31.3223 to −22.1458), as well 
as for both LVEF (95% CI: −4.0789 to −0.8232; P < 0.01) 
and GLS (Z = −5.895; P < 0.0001). However, LVEF at 
1-month and 3-months follow-ups did not differ signifi-
cantly from baseline: P = 0.644 (95% CI: −1.2230 to 1.9591) 
and P = 0.180 (95% CI: −3.1754 to 0.6137), respectively.. 
See Figures 1, 2 and 3 for box plots. 
4  Discussion 
To investigate the influence of serum 25 [OH] D correc-
tion on cardiac performance, a total of 47 older adults suf-
fering from hypovitaminosis D and cardiovascular diseases 
underwent 6-months supplementation of calcifediol. Unpre-
dictable great bioavailability of the liquid preparation forced 
us to down-titrate the dosage at 3-months assessment in 
order to maintain serum 25 [OH] D concentration under 60  
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Figure 1.  Median and interquartile ranges of serum 25 [OH] D during 6-months supplementation of calcifediol in drops. 
 
Figure 2.  Median and interquartile ranges of left ventricular ejection fraction during 6-months supplementation of calcifediol in 
drops. 
 
Figure 3.  Median and interquartile ranges of global longitudinal strain during 6-months supplementation of calcifediol in drops. 
ng/mL. Both LVEF and GLS significantly changed, but the 
GLS resulted to be an earlier predictor for left ventricular 
function amelioration at 1-month assessment. After six 
months, subjects had an average increase of LVEF of 3.94%, 
and an increase of GLS of 18.56% from baseline values. 
In this study, we may conclude that 50 μg/die of cal-
cifediol from liquid preparation was able to increase serum 
25 [OH] D concentration earlier and larger than other 
metabolic precursors.[9] Besides, 10 μg/die of liquid prepa-
ration may show better results than equivalent solid dosage 
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forms.[11] At the same times, GLS offered better insights 
into myocardial contractile amelioration than LVEF after 
serum 25[OH]D correction, thus being useful for detecting 
earlier subclinical changes that may anticipate hemody-
namic modifications.[12] 
Since major orthopedic surgery was implemented as a 
whole-scale intervention,[13] pre-operative assessments be-
came significantly important in order to identify risk factors 
for complications, such as the presence of hypovitaminosis 
D or cardiovascular disease. Aging may predispose to hy-
povitaminosis D and consequent hypocalcaemia could pos-
sibly interfere with cardiac function,[14,15] thus negatively 
altering ventricular output.[16] Besides, the resulting activa-
tion of renin-angiotensin-aldosterone system from vitamin 
D deficiency was suggested to be involved in high blood 
pressure and atrial fibrillation.[17] Our data showed that 
pre-surgery vitamin D status evaluation could be a crucial 
step to an effective treatment plan in order to ameliorate 
cardiac performance. Possibly, its measurement should be 
done even 1-month prior surgery in order to allow time for 
treatment and obtain greater results. Moreover, we showed 
that a liquid preparation proved to be effective in normaliz-
ing plasma levels in a short time, thus highlighting the im-
portance of considering the correct metabolite and dosage 
for supplementation protocols. More extensive studies 
should evaluate cardiac effects of vitamin D correction in-
cluding larger sample size and a control group, and also 
augmenting technical information about dosage forms. Rig-
orous protocols for detection and discrimination between 
cardiac and musculoskeletal effects should be applied, but 
GLS definitely proved to be useful for detecting subclinical 
cardiac changes. 
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